{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dysmyelopoietic+Syndromes&page=2", "query": { "condition": "Dysmyelopoietic Syndromes", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dysmyelopoietic+Syndromes&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-25T04:22:53.712Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00313586", "title": "Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL", "Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA", "Alkylating Agent-Related Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndrome", "Previously Treated Myelodysplastic Syndrome", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndrome", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 197, "start_date": "2006-08", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2017-02-02", "last_synced_at": "2026-07-25T04:22:53.712Z", "location_count": 234, "location_summary": "Scottsdale, Arizona • Burbank, California • Los Angeles, California + 146 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Roseville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00313586" }, { "nct_id": "NCT05115630", "title": "Off-the-shelf NK Cells + SCT for Myeloid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloid Malignancies", "Acute Myeloid Leukemia", "Myelodysplastic Syndrome", "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Fludarabine phosphate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Total Body Irradiation One Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2022-04-08", "completion_date": "2025-05-15", "has_results": true, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-07-25T04:22:53.712Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05115630" }, { "nct_id": "NCT04139434", "title": "Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML/MDS", "CMML", "Relapse", "Refractory Acute Lymphoblastic Leukemia", "Relapse Leukemia", "Relapsed Adult AML" ], "interventions": [ { "name": "LP-108", "type": "DRUG" }, { "name": "LP-108 and azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Newave Pharmaceutical Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2020-07-06", "completion_date": "2025-12-19", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-07-25T04:22:53.712Z", "location_count": 4, "location_summary": "Ann Arbor, Michigan • Cincinnati, Ohio • Columbus, Ohio + 1 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Huston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04139434" }, { "nct_id": "NCT00956787", "title": "Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arno Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2009-06", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2014-06-24", "last_synced_at": "2026-07-25T04:22:53.712Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00956787" }, { "nct_id": "NCT00260065", "title": "A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2005-05", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2013-05-20", "last_synced_at": "2026-07-25T04:22:53.712Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Boca Raton, Florida + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00260065" }, { "nct_id": "NCT02743611", "title": "Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome", "Uveal Melanoma" ], "interventions": [ { "name": "BPX-701", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bellicum Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2017-04-14", "completion_date": "2020-07-19", "has_results": true, "last_update_posted_date": "2023-10-05", "last_synced_at": "2026-07-25T04:22:53.712Z", "location_count": 3, "location_summary": "Denver, Colorado • Portland, Oregon • Nashville, Tennessee", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02743611" }, { "nct_id": "NCT00795769", "title": "Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Disseminated Neuroblastoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Poor Prognosis Metastatic Gestational Trophoblastic Tumor", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Neuroblastoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Splenic Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage II Ovarian Epithelial Cancer", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Ovarian Epithelial Cancer", "Stage III Small Lymphocytic Lymphoma", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Breast Cancer", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Ovarian Epithelial Cancer", "Stage IV Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "ondansetron", "type": "DRUG" }, { "name": "survey administration", "type": "OTHER" }, { "name": "management of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 49, "start_date": "2008-08-08", "completion_date": "2009-06-10", "has_results": true, "last_update_posted_date": "2017-05-23", "last_synced_at": "2026-07-25T04:22:53.712Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00795769" }, { "nct_id": "NCT05201066", "title": "Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Leukemia, Myelomonocytic, Chronic" ], "interventions": [ { "name": "decitabine", "type": "DRUG" }, { "name": "spartalizumab", "type": "DRUG" }, { "name": "sabatolimab", "type": "DRUG" }, { "name": "azacitidine", "type": "DRUG" }, { "name": "venetoclax", "type": "DRUG" }, { "name": "INQOVI (oral decitabine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "12 Years to 99 Years" }, "enrollment_count": 33, "start_date": "2023-02-28", "completion_date": "2028-02-14", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-07-25T04:22:53.712Z", "location_count": 2, "location_summary": "Portland, Oregon • Salt Lake City, Utah", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05201066" }, { "nct_id": "NCT00376480", "title": "Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "peripheral blood lymphocyte therapy", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "50 Years", "sex": "ALL", "summary": "Up to 50 Years" }, "enrollment_count": 19, "start_date": "2005-06", "completion_date": "2018-05-16", "has_results": false, "last_update_posted_date": "2019-07-05", "last_synced_at": "2026-07-25T04:22:53.712Z", "location_count": 6, "location_summary": "Los Angeles, California • Gainesville, Florida • Boston, Massachusetts + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376480" }, { "nct_id": "NCT01422486", "title": "Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome (MDS)" ], "interventions": [ { "name": "ezatiostat hydrochloride (Telintra®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telik", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2011-10", "completion_date": "2013-02", "has_results": false, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-07-25T04:22:53.712Z", "location_count": 5, "location_summary": "Maywood, Illinois • Springfield, Illinois • Bethesda, Maryland + 2 more", "locations": [ { "city": "Maywood", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01422486" } ] }